Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed invasive breast cancer meeting the following criteria: * Early-stage disease * No stage IV disease * More than one synchronous primary breast tumor * Lymph node positive OR high-risk lymph node negative * Candidate for treatment with anthracycline- and taxane-based chemotherapy in the adjuvant setting * Must begin therapy within 84 days after the final required surgical procedure * HER2/neu-negative breast cancer, defined as an immunohistochemistry (IHC) score of 0, 1+ or 2+ and fluorescent in situ hybridization (FISH) not amplified * No CNS disease (e.g., primary brain tumor or brain metastasis) * Hormone receptor status known PATIENT CHARACTERISTICS: * Male or female * Pre- or post-menopausal * ECOG performance status 0-1 * Absolute neutrophil count ≥ 1,000/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Bilirubin normal * AST or ALT ≤ 2.5 times upper limit of normal * Creatinine normal OR creatinine clearance ≥ 60 mL/min * Urine protein:creatinine ratio ≤ 1.0 * PT and PTT normal * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after completion of study therapy * LVEF normal by MUGA scan at baseline * No significant bleeding within the past 6 months * No uncontrolled underlying bleeding diathesis * No nonmalignant systemic disease (e.g., cardiovascular, renal, or hepatic) that would preclude study therapy, including any of the following conditions: * Blood pressure \> 150/100 mm Hg * Unstable angina * New York Heart Association class II -IV congestive heart failure * Myocardial infarction or stroke within the past 12 months * Clinically significant peripheral vascular disease * No seizures not controlled with standard medical therapy * No history of stroke * No known allergy or hypersensitivity to study drugs (prior hypersensitivity to paclitaxel allowed) * No significant traumatic injury within the past 28 days * No serious nonhealing wound, ulcer, or bone fracture * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * No active gastroduodenal ulcer * No uncontrolled intercurrent illness, including psychiatric illness or social situation that would limit compliance with study requirements PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Prior therapy for an ipsilateral or contralateral breast cancer primary allowed provided the following criteria are met: * No prior anthracycline therapy * Prior hormonal therapy for this previous breast cancer is allowed, but must be stopped during study therapy * At least 1 year since prior taxane therapy * More than 28 days since prior and no concurrent major surgery or open biopsy * Anticipated reconstructive surgery (e.g., tissue expander exchange) is allowed during the course of the study (bevacizumab will be held during that time as per protocol guidelines) * More than 7 days since prior minor surgery, including fine-needle aspiration or core biopsy * At least 24 hours since prior indwelling catheter placement * No prior bevacizumab or other KDR inhibitors (e.g., VEGF Trap, semaxanib, SU6668, vandetanib, vatalanib, AEE788, or IMC-1CII) * No concurrent full-dose anticoagulation therapy * No concurrent hormonal therapy as chemoprevention * Concurrent participation in adjuvant hormone therapy or correlative or companion (e.g., bisphosphonate clinic) studies allowed * No other concurrent anticancer therapy